← FDA DRUG APPROVALS

FDA NDA · NDA217159

APHEXDA

motixafortide

Sponsor: AYRMID PHARMA

APPLICATION
NDA217159
TYPE
NDA
ORIGINAL APPROVAL
2023-09-08
LATEST ACTION
2026-03-11
ROUTE
SUBCUTANEOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

APHEXDA · ReferencePrescription
MOTIXAFORTIDE ACETATE EQ 62MG BASE/VIAL · POWDER · SUBCUTANEOUS

Approval history

2026-03-11Labeling · Supplement 9 · standard — Label ↗AP
2023-09-08Type 1 - New Molecular Entity · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →